Related Experiment Videos
The Japanese trophoblastic disease classification
1Department of Obstetrics and Gynecology, Tama-Nagayama Hospital, Nippon Medical School, 1-7-1, Nagayama, Tama City, Tokyo, Japan 206-8512. sasakimd@rr.iij4u.or.jp
The Journal of Reproductive Medicine
|October 2, 2004
Summary
The diagnostic score effectively identifies choriocarcinoma in persistent gestational trophoblastic disease, showing high sensitivity and specificity. This aids in early diagnosis and appropriate chemotherapy selection for better patient outcomes.
Area of Science:
- Gynecology
- Oncology
- Diagnostic Medicine
Background:
- Gestational trophoblastic disease (GTD) requires accurate diagnosis for effective management.
- Differentiating choriocarcinoma from other forms of GTD, especially without histologic confirmation, presents a clinical challenge.
Purpose of the Study:
- To assess the clinical utility of a "diagnostic score" for detecting choriocarcinoma in cases of persistent GTD lacking histologic findings.
- To evaluate the score's performance in distinguishing choriocarcinoma from invasive mole.
Main Methods:
- Retrospective analysis of clinical records and histologic reports from 809 patients with persistent GTD.
- Application of the "diagnostic score" to patients diagnosed with choriocarcinoma (347 cases) and invasive mole (462 cases).
Main Results:
- The diagnostic score demonstrated a sensitivity of 91.4% for choriocarcinoma detection.
- The score achieved a specificity of 94.1% for identifying invasive mole.
- Overall accuracy of the diagnostic score was 92.8%.
Conclusions:
- The diagnostic score is a valuable tool for the clinical differentiation of choriocarcinoma in persistent GTD.
- It assists in selecting appropriate chemotherapy regimens and potentially comparing international treatment outcomes.
- Early and accurate diagnosis through this scoring system is crucial for improving patient prognosis.